Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning

Bone Marrow Transplantation

Volumn 37, Issue 3, 2006, Pages 307-310

  Kline, J ^a   Pollyea, D A ^a   Stock, W ^a   Artz, A ^a   Rich, E ^a   Godley, L ^a   Zimmerman, T ^a   Thompson, K ^a   Pursell, K ^a   Larson, R A ^a   van Besien, K ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Alemtuzumab; Allogeneic transplant; CMV; T cell depletion; Valacyclovir

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; FLUDARABINE; GANCICLOVIR; MELPHALAN; TSUKUBAENOLIDE; VALACICLOVIR;

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

ACYCLOVIR; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VALINE;

EID: 33645290002     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705249     Document Type: Article

References (12)

1. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071-1078.
2. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
3. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
4. van Besien K, Artz A, Smith S, Cao D-C, Rich S, Godley L et al. Fludarabine melphalan alemtuzumab (Campath-1H®) conditioning in adults with advanced AML and MDS. Excellent outcomes in patients with standard risk disease. J Clin Oncol 2005; 23: 5728-5738.
5. Ljungman P, De la Camara R, Milpied N, Volin L, Russell CA, Crisp A et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002; 99: 3050-3056.
6. van Besien K, Smith S, Odenike O, Daugherty C, Zimmerman T, Thirman MJ et al. Alemtuzumab (Campath)-based GVHD prophylaxis leads to improved survival after allogeneic transplantation for patients with advanced hematologic malignancies. Blood 102; 2611: 2003.
7. Meyers JD, Reed EC, Shepp DH. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70-75.
8. Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D et al. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant 2003; 31: 813-816.
9. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543-558.
10. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159-1164.
11. Atkinson K, Downs K, Golenia M, Biggs J, Marshall G, Dodds A et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: Absence of clinical cytomegalovirus infection. Brit J Haematol 1991; 79: 57-62.
12. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: Results of a placebo-controlled, double-blind trial. Ann Int Med 1993; 118: 179-184.